STOCK TITAN

IONS insider files Form 144 to sell 27,114 shares valued at $1.79M

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

IONIS PHARMACEUTICALS, INC. (IONS) submitted a Form 144 reporting a proposed sale of 27,114 shares of common stock through Stifel Nicolaus & Company on Nasdaq, with an aggregate market value of $1,789,524 and total shares outstanding reported as 159,391,229. The filer reports acquiring 17,114 of these shares on 01/15/2021 by option exercise, with payment listed as cash and an approximate sale date of 10/01/2025.

The filing also discloses a prior sale by the same person on 09/02/2025 of 11,130 shares for $552,865. By simple proportion, the proposed sale represents approximately 0.017% of outstanding shares, indicating the transaction is small relative to the company's share count. The notice contains the standard insider representation about absence of undisclosed material information.

Positive

  • Compliance disclosure provided with broker, share counts, aggregate value, acquisition method and prior sale details
  • Full transparency about acquisition date (01/15/2021) and nature (option exercise), facilitating investor review

Negative

  • Insider selling is disclosed (proposed sale of 27,114 shares and prior sale of 11,130 shares), which some investors may view negatively even though scale is small

Insights

TL;DR Routine Rule 144 filing documenting a small insider sale and prior recent disposition; consistent with compliance obligations.

This Form 144 supplies required details: broker, number of shares proposed, aggregate value, acquisition method (option exercise), and a prior sale within the past three months. The filing helps ensure the seller meets resale conditions under Rule 144 and provides market transparency. No indication in the form of undisclosed material information is provided by the signer, which is standard and required. The proposed sale size (~0.017% of outstanding shares) is immaterial from a market-impact perspective.

TL;DR Insider sale disclosed but quantitatively negligible versus total shares outstanding; unlikely to change investor valuation materially.

The reported aggregate value ($1.79M) and prior gross proceeds ($552.9k) give transparency on insider liquidity. The acquisition date and method (01/15/2021, option exercise) explain the origin of the shares sold. Given the small percentage of outstanding shares being sold, this notice appears informational rather than signaling a material shift in insider conviction. Investors may note the timing and aggregation of recent sales but the scale is not significant relative to market capitalization based on reported outstanding shares.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed by IONS report?

The form reports a proposed sale of 27,114 common shares through Stifel Nicolaus on Nasdaq with an aggregate market value of $1,789,524 and an approximate sale date of 10/01/2025.

How many shares did the filer acquire and how were they acquired?

The filing states 17,114 shares were acquired on 01/15/2021 by option exercise and payment is listed as cash.

Did the filer sell any shares recently prior to this proposed sale?

Yes. The filer sold 11,130 shares on 09/02/2025 for gross proceeds of $552,865.

How material is the proposed sale relative to outstanding shares?

Based on the filing's reported outstanding shares (159,391,229), the proposed sale of 27,114 shares is approximately 0.017% of outstanding shares, indicating a negligible market impact.

Who is handling the sale according to the filing?

The broker named on the Form 144 is Stifel Nicolaus & Company Inc, located in St. Louis, MO.
Ionis Pharmaceuticals

NASDAQ:IONS

IONS Rankings

IONS Latest News

IONS Latest SEC Filings

IONS Stock Data

12.90B
160.75M
0.65%
108.48%
6.59%
Biotechnology
Pharmaceutical Preparations
Link
United States
CARLSBAD